Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
As part of the reorganization, Myriad signed a definitive agreement to sell its EndoPredict® business to Eurobio Scientific, a leading French group in in vitro medical diagnostics and life sciences.
- As part of the reorganization, Myriad signed a definitive agreement to sell its EndoPredict® business to Eurobio Scientific, a leading French group in in vitro medical diagnostics and life sciences.
- Myriad will also license Eurobio the right to sell Prolaris in vitro diagnostic kits outside the U.S.
- “The change in our international strategy is part of our continued effort to accelerate profitable growth while supporting our biopharma partners in the most efficient manner,” said Paul J. Diaz, president and CEO of Myriad Genetics.
- “By divesting the EndoPredict business to Eurobio, we believe EndoPredict and our European teammates will have more opportunities to grow given Eurobio’s strength and presence in the European market.